14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
CMCSA vs CVS: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 20, 2026, Comcast Corp (CMCSA) is the stronger overall head-to-head candidate over Cvs Health Corporation (CVS) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). CMCSA carries a Unified Composite Score of 32.8/100 (SELL) at $24.90 (7.1x Forward P/E, 14.7% operating margin), whereas CVS carries 62.6/100 (BUY) at $80.84 (9.3x Forward P/E, 3.1% operating margin).
Composite vs. Pillar Nuance: While CVS currently prints a higher short-term Unified Composite Score (62.6/100 BUY vs. CMCSA 32.8/100 SELL), CMCSA captures the overall institutional head-to-head verdict (6–4 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (14.7% vs. 3.1% operating margin) and revenue trajectory (-6.1% vs. +5.4% YoY).
Technical & Structure Timing Caution: CMCSA trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 59.9); meanwhile CVS is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 36.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Competes within the Healthcare Plans value chain with $102.4B market capitalization and 3.1% operating margin.
OpEx & R&D Reinvestment10.6% of Rev ($44.3B)
90D Engineering Disclosures0 Published
Investor FAQ CMCSA vs CVS Key Questions & Quantitative Answers
As of Nov 20, 2026, Comcast Corp (CMCSA) is the stronger overall head-to-head candidate over Cvs Health Corporation (CVS) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). CMCSA carries a Unified Composite Score of 32.8/100 (SELL) at $24.90 (7.1x Forward P/E, 14.7% operating margin), whereas CVS carries 62.6/100 (BUY) at $80.84 (9.3x Forward P/E, 3.1% operating margin). Composite vs. Pillar Nuance: While CVS currently prints a higher short-term Unified Composite Score (62.6/100 BUY vs. CMCSA 32.8/100 SELL), CMCSA captures the overall institutional head-to-head verdict (6–4 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (14.7% vs. 3.1% operating margin) and revenue trajectory (-6.1% vs. +5.4% YoY). Technical & Structure Timing Caution: CMCSA trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 59.9); meanwhile CVS is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 36.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
CVS leads the Growth & Scale pillar: CMCSA posts -6.1% YoY revenue growth and +7.8% YoY earnings growth on $123.0B TTM revenue (69.8% gross margin, 14.7% operating margin), compared with CVS at +5.4% YoY revenue growth and +188.8% YoY earnings growth on $418.2B TTM revenue (13.7% gross margin, 3.1% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), CMCSA cumulative revenue shifted +30.9% while CVS shifted +107.3%. In operating R&D and SG&A reinvestment, CMCSA deploys 55.1% of Rev ($67.8B) (0 90-day corporate R&D disclosures) versus 10.6% of Rev ($44.3B) (0 disclosures) for CVS.
CMCSA screens cheaper on headline valuation multiples. CMCSA trades at 7.1x Forward P/E, 7.9x Trailing P/E, 1.37x PEG, and 1.4x EV/Revenue (13.9% FCF margin), whereas CVS trades at 9.3x Forward P/E, 9.3x Trailing P/E, 0.20x PEG, and 0.4x EV/Revenue (3.7% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CMCSA (11.4% ROE) versus CVS (14.4% ROE) capital efficiency.
In options market volatility and institutional positioning, CMCSA carries 36.3% implied volatility (30th %ile, Balanced (25th–60th %ile)), a 0.41x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (-0.01β · 32% Vol realized risk). By comparison, CVS carries 86.2% implied volatility (69th %ile, Elevated (60th–80th %ile)), a 0.62x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (-0.03β · 54% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.